Incendia Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 38th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Incendia Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will present three posters at the Society for Immunotherapy of Cancer (SITC) 38^th Annual Meeting, to be held in San Diego, California November 1-5, 2023.

“We look forward to presenting three posters at SITC which validate our approach to block Discoidin Domain Receptor 1 (DDR1) and advance our understanding of and ability to detect immune exclusion in solid tumors,” said Laura Dillon, PhD, VP, Translational Medicine & Bioinformatics at Incendia Therapeutics. “We are encouraged by the human tumor data in intrahepatic cholangiocarcinoma (iCCA), which demonstrate a correlation of high DDR1 expression with worse prognosis in all stages of disease. The prevalence of high DDR1 expression and poor survival outcomes associated with this make iCCA a relevant tumor type for evaluating novel DDR1-targeted therapies.”

Presentation Details for SITC 2023 are as follows:

Title: DDR1 expression is associated with a worse prognosis in intrahepatic cholangiocarcinoma
Poster number: 1486
Presenter: Travis Clifton, MD, Co-founder, Head of Clinical Sciences
Time: Saturday, November 4, 12:15-1:45 PM PDT and 5:30-7:00 PM PDT (3:15-4:45 PM EDT and 8:30-10 PM EDT)
Location: Poster Hall (Exhibit Hall B)

Title: The epithelium-stroma interface serves as a barrier to immune cell infiltration across tumor immune phenotypes in epithelial cancers
Poster number: 1497
Presenter: Laura Dillon, Ph.D., VP, Translation Medicine & Bioinformatics
Time: Friday, November 3, 12:15-1:45 PM PDT and 5:30-7:00 PM PDT (3:15-4:45 PM EDT and 8:30-10 PM EDT)
Location: Poster Hall (Exhibit Hall B)

Title: Comparison of multiplex immunofluorescence and H&E-based approaches for characterization of the tumor microenvironment
Poster number: 1287
Presenter: Fredrick Gootkind, M.S., Senior Associate Scientist
Time: Friday, November 3, 12:15-1:45 PM PDT and 5:30-7:00 PM PDT (3:15-4:45 PM EDT and 8:30-10 PM EDT)
Location: Poster Hall (Exhibit Hall B)

About Incendia Therapeutics

Incendia Therapeutics is discovering and developing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). Recent research has shown that the interplay between tumor cells and their surrounding TME results in the creation of barriers that markedly attenuate the immune system’s ability to attack the tumor. Based on rigorous, groundbreaking research, Incendia is developing a portfolio of drug candidates to treat select patients at the appropriate/ideal stage in disease progression. The company’s lead program, PRTH-101, is a monoclonal antibody targeting Discoiding Domain Receptor 1 (DDR1). It seeks to break down collagen barriers in solid tumors to promote tumor killing by the immune system, therby overcoming recalcitrant tumors. PRTH-101 is currently being evaluated in Phase 1 clinical trials (NCT05753722). For more information visit incendia.com and LinkedIn.